

**bs-23028R****[ Primary Antibody ]****ACE2 Rabbit pAb****BioSS**  
**ANTIBODIES**

www.bioss.com.cn


sales@bioss.com.cn

techsupport@bioss.com.cn


400-901-9800

**— DATASHEET —**

<b>Host:</b> Rabbit <b>Clonality:</b> Polyclonal <b>GeneID:</b> 59272 <b>Target:</b> ACE2 <b>Immunogen:</b> KLH conjugated synthetic peptide derived from human ACE2: 551-650/805. < Extracellular > <b>Purification:</b> affinity purified by Protein A <b>Concentration:</b> 1mg/ml <b>Storage:</b> 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. <b>Background:</b> The protein encoded by this gene belongs to the angiotensin-converting enzyme family of dipeptidyl carboxydipeptidases and has considerable homology to human angiotensin 1 converting enzyme. This secreted protein catalyzes the cleavage of angiotensin I into angiotensin 1-9, and angiotensin II into the vasodilator angiotensin 1-7. The organ- and cell-specific expression of this gene suggests that it may play a role in the regulation of cardiovascular and renal function, as well as fertility. In addition, the encoded protein is a functional receptor for the spike glycoprotein of the human coronaviruses SARS and HCoV-NL63. [provided by RefSeq, Jul 2008]	<b>Isotype:</b> IgG <b>SWISS:</b> Q9BYF1	<b>Applications:</b> <b>Flow-Cyt</b> (2ug/Test) <b>ICC/IF</b> (1:100-500) <b>Reactivity:</b> Human (predicted: Mouse, Rat) <b>Predicted MW.:</b> 87 kDa <b>Subcellular Location:</b> Cytoplasm ,Cell projection ,Membrane ,Secreted ,Cell membrane
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**— VALIDATION IMAGES —**

SHSY5Y cell; 4% Paraformaldehyde-fixed; Triton X-100 at room temperature for 20 min; Blocking buffer (normal goat serum, C-0005) at 37°C for 20 min; Antibody incubation with (ACE2) polyclonal Antibody, Unconjugated (bs-23028R) 1:100, 90 minutes at 37°C; followed by a conjugated Goat Anti-Rabbit IgG antibody at 37°C for 90 minutes, DAPI (blue, C02-04002) was used to stain the cell nuclei.



Blank control: HepG2. Primary Antibody (green line): Rabbit Anti-ACE2 antibody (bs-23028R) Dilution: 2µg /10<sup>6</sup> cells; Isotype Control Antibody (orange line): Rabbit IgG . Secondary Antibody : Goat anti-rabbit IgG-AF488 Dilution: 1µg /test. Protocol The cells then incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 10,000 events was performed.

**— SELECTED CITATIONS —**

- **[IF=6.823]** Dina Khateeb. et al. SARS-CoV-2 variants with reduced infectivity and varied sensitivity to the BNT162b2 vaccine are developed during the course of infection. Plos Pathog. 2022 Jan;18(1):e1010242 FCM ;Human. 35020754